Polygenic Scores and Preclinical Cardiovascular Disease in Individuals With HIV: Insights From the REPRIEVE Trial
Journal of the American Heart Association · 2024
DOI: 10.1161/jaha.123.033413 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, 2024. Verfasst von Roger S Zou und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine Massachusetts General Hospital Boston MA USA. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Coronary Artery Disease, Plaque, Atherosclerotic, Atherosclerosis. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIGMS NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
Background
Coronary artery disease (CAD) is a leading cause of death among the 38.4 million people with HIV globally. The extent to which cardiovascular polygenic risk scores (PRSs) derived in non‐HIV populations generalize to people with HIV is not well understood. Methods and Results PRSs for CAD (GPS Mult ) and lipid traits were calculated in a global cohort of people with HIV treated with antiretroviral therapy with low‐to‐moderate atherosclerotic cardiovascular disease risk enrolled in REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV). The PRSs were associated with baseline lipid traits in 4495 genotyped participants, and with subclinical CAD in a subset of 662 who underwent coronary computed tomography angiography. Among participants who underwent coronary computed tomography angiography (mean age, 50.9 [SD, 5.8] years; 16.1% women; 41.8% African, 57.3% European, 1.1% Asian), GPS Mult was associated with plaque presence with odds ratio (OR) per SD in GPS Mult of 1.42 (95% CI, 1.20–1.68; P =3.8×10 −5 ), stenosis >50% (OR, 2.39 [95% CI, 1.48–3.85]; P =3.4×10 −4 ), and noncalcified/vulnerable plaque (OR, 1.45 [95% CI, 1.23–1.72]; P =9.6×10 −6 ). Effects were consistent in subgroups of age, sex, 10‐year atherosclerotic cardiovascular disease risk, ancestry, and CD4 count. Adding GPS Mult to established risk factors increased the C‐statistic for predicting plaque presence from 0.718 to 0.734 ( P =0.02). Furthermore, a PRS for low‐density lipoprotein cholesterol was associated with plaque presence with OR of 1.21 (95% CI, 1.01–1.44; P =0.04), and partially calcified plaque with OR of 1.21 (95% CI, 1.01–1.45; P =0.04) per SD.
Conclusions
Among people with HIV treated with antiretroviral therapy without documented atherosclerotic cardiovascular disease and at low‐to‐moderate calculated risk in REPRIEVE, an externally developed CAD PRS was predictive of subclinical atherosclerosis. PRS for low‐density lipoprotein cholesterol was also associated with subclinical atherosclerosis, supporting a role for low‐density lipoprotein cholesterol in HIV‐associated CAD. Registration URL: https://www.reprievetrial.org ; Unique identifier: NCT02344290.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine Massachusetts General Hospital Boston MA USA.
- Cardiovascular Disease Initiative Broad Institute of MIT and Harvard Cambridge MA USA.
- Harvard Medical School Boston MA USA.
- Division of Cardiology, Department of Medicine, Center for Genomic Medicine Massachusetts General Hospital Boston MA USA.
- Cardiovascular Imaging Research Center Massachusetts General Hospital and Harvard Medical School Boston MA USA.
- Metabolism Unit Massachusetts General Hospital Boston MS USA.
ORCID-Profile: Roger S Zou, Yunfeng Ruan, Buu Truong, Romit Bhattacharya, Michael T Lu, Júlia Karády, Rachel Bernardo, Whitney Hornsby, Kathleen V Fitch, Heather J Ribaudo, Markella V Zanni, Pamela S Douglas, Aniruddh P Patel, Pradeep Natarajan
Förderung
- NHLBI NIH HHS
- NIGMS NIH HHS
- NIAID NIH HHS
- NIDDK NIH HHS
- NHGRI NIH HHS
Zitieren
APA
Zou, R. S., Ruan, Y., Truong, B., Bhattacharya, R., Lu, M. T., Karády, J., Bernardo, R., Finneran, P., Hornsby, W., Fitch, K. V., Ribaudo, H. J., Zanni, M. V., Douglas, P. S., Grinspoon, S. K., Patel, A. P., & Natarajan, P. (2024). Polygenic Scores and Preclinical Cardiovascular Disease in Individuals With HIV: Insights From the REPRIEVE Trial. Journal of the American Heart Association. https://doi.org/10.1161/jaha.123.033413
Vancouver
Zou RS, Ruan Y, Truong B, Bhattacharya R, Lu MT, Karády J, et al. Polygenic Scores and Preclinical Cardiovascular Disease in Individuals With HIV: Insights From the REPRIEVE Trial. Journal of the American Heart Association. 2024. doi:10.1161/jaha.123.033413
BibTeX
@article{Zou2024,
author = {Zou, Roger S and Ruan, Yunfeng and Truong, Buu and Bhattacharya, Romit and Lu, Michael T and Karády, Júlia and Bernardo, Rachel and Finneran, Phoebe and Hornsby, Whitney and Fitch, Kathleen V and Ribaudo, Heather J and Zanni, Markella V and Douglas, Pamela S and Grinspoon, Steven K and Patel, Aniruddh P and Natarajan, Pradeep},
title = {Polygenic Scores and Preclinical Cardiovascular Disease in Individuals With HIV: Insights From the REPRIEVE Trial},
journal = {Journal of the American Heart Association},
year = {2024},
doi = {10.1161/jaha.123.033413}
}
EUVIMED